期刊
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
卷 18, 期 -, 页码 101-111出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.nano.2019.02.014
关键词
Sodium colistimethate; Lipid nanoparticle; NLC; Pseudomonas aeruginosa
资金
- TERFIQEC Project - Ministry of Economy and Competitiveness MINECO, Spain [IPT-2011-1402-900000]
- University of the Basque Country UPV/EHU [UFI11/32]
- HUA
- VHIR
- UIB
- CSIC-FISIB Caubet-Cimera
- UPV/EHU
- ESCMID [Protneb-Par PI13/02551]
The usefulness of nanotechnology to increase the bioavailability of drugs and decrease their toxicity may be a tool to deal with multiresistant P. aeruginosa (Mr-Pa) respiratory infections. We describe the preparation and the in vivo efficacy and safety of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) by the pulmonary and intramuscular routes. Nanoparticles showed 1-2 mg/L minimum inhibitory concentration against eight extensively drug-resistant P. aeruginosa strains. In vivo. SCM-NLC displayed significantly lower CFU/g lung than the saline and similar to that of the free SCM, even the dose in SCM-NLC group was lower than free SCM. There was no tissue damage related to the treatments. Biodistribution assessments showed a mild systemic absorption after nebulization and a notorious absorption after IM route. Altogether, it could be concluded that SCM-NLC were effective against P. aeruginosa in vivo, not toxic and distribute efficiently to the lung and liver after pulmonary or intramuscular administrations. (C) 2019 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据